Sutro Biopharma, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own0.10% Shs Outstand57.48M Perf Week-4.64%
Market Cap412.71M Forward P/E- EPS next Y-2.76 Insider Trans0.00% Shs Float54.23M Perf Month0.84%
Income-122.70M PEG- EPS next Q-0.62 Inst Own91.30% Short Float / Ratio3.90% / 3.61 Perf Quarter2.57%
Sales69.80M P/S5.91 EPS this Y-132.00% Inst Trans13.20% Short Interest2.11M Perf Half Y22.91%
Book/sh4.39 P/B1.64 EPS next Y-6.90% ROA-34.30% Target Price22.12 Perf Year-28.53%
Cash/sh5.65 P/C1.27 EPS next 5Y- ROE-53.80% 52W Range3.33 - 10.78 Perf YTD-11.01%
Dividend- P/FCF- EPS past 5Y- ROI-35.50% 52W High-33.30% Beta0.91
Dividend %- Quick Ratio5.90 Sales past 5Y0.70% Gross Margin- 52W Low115.92% ATR0.49
Employees259 Current Ratio5.90 Sales Q/Q195.30% Oper. Margin- RSI (14)44.40 Volatility4.63% 7.29%
OptionableYes Debt/Eq0.08 EPS Q/Q44.40% Profit Margin- Rel Volume0.40 Prev Close7.50
ShortableYes LT Debt/Eq0.03 EarningsNov 08 AMC Payout- Avg Volume585.04K Price7.19
Recom1.80 SMA20-7.23% SMA50-4.48% SMA20015.76% Volume235,561 Change-4.13%
Aug-18-22Resumed Wells Fargo Overweight $15
Jun-18-21Initiated H.C. Wainwright Buy $35
Dec-03-20Initiated Stifel Buy $25
Sep-02-20Initiated Jefferies Buy $21
Jul-16-20Initiated Wells Fargo Overweight $18
Jan-13-20Initiated SunTrust Buy $18
Oct-07-19Initiated BTIG Research Buy $19
Jul-18-19Initiated Deutsche Bank Buy $22
Apr-29-19Initiated H.C. Wainwright Buy $18
Oct-22-18Initiated Wedbush Outperform $20
Show Previous Ratings
Jan-27-23 06:31AM
Jan-10-23 09:06AM
Jan-09-23 04:05PM
Jan-06-23 01:48PM
Jan-04-23 08:00AM
08:00AM Loading…
Dec-21-22 08:00AM
Dec-20-22 04:05PM
Dec-17-22 07:42AM
Dec-10-22 10:30AM
Nov-23-22 07:00AM
Nov-20-22 07:07AM
Nov-11-22 09:55AM
Nov-08-22 05:45PM
09:00AM Loading…
Nov-03-22 09:00AM
Nov-02-22 10:00AM
Oct-24-22 07:00AM
Oct-21-22 09:55AM
Oct-05-22 09:55AM
Sep-26-22 09:39AM
Sep-19-22 11:58AM
Sep-01-22 07:00AM
Aug-29-22 09:55AM
Aug-19-22 04:01PM
Aug-11-22 09:55AM
Aug-08-22 06:05PM
07:00AM Loading…
Aug-03-22 07:00AM
Jul-28-22 08:07AM
Jul-26-22 04:01PM
Jul-12-22 07:00AM
Jun-29-22 11:51AM
Jun-28-22 12:25PM
Jun-27-22 07:31PM
Jun-03-22 04:01PM
Jun-02-22 07:00AM
May-14-22 08:02AM
May-09-22 05:45PM
May-05-22 05:35PM
Apr-29-22 05:00PM
Apr-19-22 09:30AM
Apr-08-22 01:00PM
Apr-05-22 07:00AM
Mar-30-22 04:05PM
Mar-21-22 01:39PM
Mar-03-22 07:00AM
Feb-28-22 04:35PM
Feb-18-22 11:21AM
Feb-17-22 02:38AM
Jan-07-22 08:48AM
Jan-06-22 04:34PM
Jan-05-22 04:30PM
Dec-27-21 07:00AM
Dec-17-21 01:38PM
Dec-13-21 07:00AM
Nov-22-21 07:00AM
Nov-17-21 07:00AM
Nov-10-21 08:55AM
Nov-02-21 07:00AM
Oct-28-21 03:05PM
Oct-19-21 11:19AM
Oct-13-21 03:07AM
Oct-12-21 07:00AM
Sep-30-21 09:18AM
Sep-29-21 10:26AM
Sep-17-21 05:00PM
Sep-16-21 07:00AM
Sep-01-21 07:00AM
Aug-19-21 09:35AM
Aug-18-21 07:37AM
Aug-11-21 08:12AM
Aug-09-21 08:35AM
Aug-05-21 10:50AM
Jul-29-21 03:05PM
Jul-13-21 11:11AM
Jun-21-21 04:42PM
Jun-15-21 07:00AM
Jun-01-21 02:02PM
May-19-21 05:00PM
May-14-21 07:00AM
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chung JaneChief Commercial OfficerAug 09Option Exercise0.0018,750021,250Aug 10 06:16 PM
Vasquez NickiChief Port. Strat & Alnce OfcrJul 12Option Exercise0.003,250015,243Jul 13 06:24 PM
Hallam TrevorPres. Rsrch & Cf. Sctific OfcrApr 14Option Exercise0.003,750081,567Apr 15 07:19 PM
NEWELL WILLIAM JCEOMar 14Buy7.7510,00077,508116,525Mar 15 07:00 PM
Petree Daniel HDirectorFeb 08Option Exercise5.0814,27772,56422,265Feb 09 06:28 PM